LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Authors
Keywords
-
Journal
Cell Metabolism
Volume 34, Issue 9, Pages 1234-1247.e9
Publisher
Elsevier BV
Online
2022-08-18
DOI
10.1016/j.cmet.2022.07.013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
- (2022) Victoria E. R. Parker et al. DIABETES OBESITY & METABOLISM
- Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
- (2022) Tim Heise et al. Lancet Diabetes & Endocrinology
- Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon‐like peptide‐1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of A sian descent with or without type 2 diabetes
- (2021) Michiko Asano et al. DIABETES OBESITY & METABOLISM
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- How glucagon-like peptide 1 receptor agonists work
- (2021) Christine Rode Andreasen et al. Endocrine Connections
- Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
- (2021) Martin Bossart et al. Cell Metabolism
- 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2022
- (2021) DIABETES CARE
- A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
- (2021) Kenichi Furihata et al. DIABETES OBESITY & METABOLISM
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon
- (2021) Renata Spezani et al. LIFE SCIENCES
- GLP-1 physiology informs the pharmacotherapy of obesity
- (2021) Daniel J. Drucker Molecular Metabolism
- The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists
- (2020) Shweta Urva et al. DIABETES OBESITY & METABOLISM
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- (2020) Francis S. Willard et al. JCI Insight
- Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
- (2020) Jennifer Trujillo JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- Glucagon Control on Food Intake and Energy Balance
- (2019) Omar Al-Massadi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Glucagon Regulation of Energy Expenditure
- (2019) Maximilian Kleinert et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role of glucagon in protein catabolism
- (2018) Steven E. Thiessen et al. Current Opinion in Critical Care
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- Targeting the Incretin/Glucagon System with Triagonists to Treat Diabetes
- (2018) Megan E Capozzi et al. ENDOCRINE REVIEWS
- Hemodynamic Effects of Glucagon: A Literature Review
- (2018) Kasper Meidahl Petersen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
- (2018) Elizabeth A. Killion et al. Science Translational Medicine
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice
- (2017) Gina Song et al. PEPTIDES
- The New Biology and Pharmacology of Glucagon
- (2017) T. D. Müller et al. PHYSIOLOGICAL REVIEWS
- Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreaticβ-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes
- (2016) A. Mari et al. DIABETES OBESITY & METABOLISM
- Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
- (2016) Francesco Rubino et al. Surgery for Obesity and Related Diseases
- Reappraisal of GIP Pharmacology for Metabolic Diseases
- (2016) Brian Finan et al. TRENDS IN MOLECULAR MEDICINE
- Metabolic adaptation to caloric restriction and subsequent refeeding: the Minnesota Starvation Experiment revisited
- (2015) Manfred James Müller et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
- (2015) V. Salem et al. DIABETES OBESITY & METABOLISM
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production
- (2014) Lucy S. Jun et al. DIABETES
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials
- (2013) V. L. Gloy et al. BMJ-British Medical Journal
- Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
- (2012) T. M. Tan et al. DIABETES
- Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
- (2011) M. Christensen et al. DIABETES
- A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
- (2011) P. Barrington et al. DIABETES OBESITY & METABOLISM
- Bariatric surgery: an IDF statement for obese Type 2 diabetes
- (2011) J. B. Dixon et al. DIABETIC MEDICINE
- The metabolic actions of glucagon revisited
- (2010) Kirk M. Habegger et al. Nature Reviews Endocrinology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More